What is the 13F Pro Quality Score for PDEX?

13F Pro ranks PRO DEX INC (PDEX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PDEX's current score at https://13fpro.ai/research/PDEX (free sign-up required for the full ranking).

Where does 13F Pro source PDEX data?

All PRO DEX INC fundamentals and ownership data come directly from SEC EDGAR. PRO DEX INC files with the SEC under CIK 788920. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PDEX in?

PRO DEX INC (PDEX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives PDEX's revenue?

Per PRO DEX INC's latest 10-Q filed with the SEC on 2026-04-30, the biggest revenue drivers are: Medical device products ($45.8M, +35% YoY); Repairs ($9.7M, -36% YoY); NRE & Prototype ($1.2M, +322% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/PDEX.

What are PDEX's largest expenses?

PRO DEX INC's latest 10-Q reports these as the largest expense items: Cost of sales ($39.9M, +21% YoY); General and administrative expenses ($5.3M, +42% YoY); Research and development costs ($2.3M, -15% YoY). Sourced directly from SEC EDGAR filing text for Q3 FY2026 (nine months ended March 31, 2026).

How often is PDEX research updated on 13F Pro?

PDEX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PRO DEX INC(PDEX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 788920 PDEX stock profile & AI dashboard →

13F Pro Quality Score

69.9/100

Rank #342 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

82.1/100

Profitability

86.6/100

Balance Sheet

97.9/100

Earnings Quality

95.1/100

Free Cash Flow

64.3/100

Institutional Flow

36.0/100

Revenue Scale

14.4/100

Dilution Risk

62.1/100

PDEX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for PRO DEX INC (PDEX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PDEX at 69.9/100 on a 32-signal composite quality model, placing it at rank #342 of 2,879 stocks — the top 25% of the AI-ranked universe. PDEX scores in the top quartile across balance sheet strength (97.9), earnings quality (95.1), profitability (86.6). Areas of concern include revenue scale (14.4) and institutional flow (36.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q3 2026), PRO DEX INC reports quarterly revenue of $19.9M, net income of $3.9M, an operating margin of 15.5%. Top institutional holders of PDEX by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, PUNCH & ASSOCIATES INVESTMENT MANAGEMENT,, based on the most recent SEC filings. PDEX trades on the Nasdaq exchange and files with the SEC under CIK 788920. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PDEX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PRO DEX INC directly from SEC EDGAR. PRO DEX INC's 13F Pro composite quality score has ranged between 45 and 70 since 2024, currently 69.9 — an improving long-term trajectory across 15 quarterly and live scoring snapshots.

What's Driving PDEX's Business? Latest 10-Q Breakdown

AI-extracted from PRO DEX INC's 10-Q filed 2026-04-30 — Q3 FY2026 (nine months ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Net sales grew 16% YoY to $57.1M; acquisition of precision machining supplier APM for $8.7M completed in February 2026 to support largest customer contract extension through 2028.

Biggest Revenue Drivers

Total revenue: $57.1M+16% YoY

Medical device products$45.8M+35% YoY

Largest customer contract extension with higher volumes; orthopedic sales up $11.4M YoY.

Repairs$9.7M-36% YoY

Fewer repairs of legacy orthopedic handpiece; customer may be replacing with next generation.

NRE & Prototype$1.2M+322% YoY

Increase in billable contracts for various NRE projects undertaken for customers.

Industrial and scientific$836K+45% YoY

Includes APM sales from acquisition date of February 9, 2026.

Largest Expense Items

Cost of sales$39.9M+21% YoY

Increase consistent with 16% revenue growth; includes $2.3M under-absorption of manufacturing costs and $687K inventory/warranty charges.

General and administrative expenses$5.3M+42% YoY

Increased personnel costs ($500K), APM subsidiary expenses ($233K), consulting fees from APM seller ($250K), and CEO bonus accrual ($225K).

Research and development costs$2.3M-15% YoY

Decrease due to higher billable project expenses reclassified to cost of sales and reduced IP legal costs; excludes prior-year recruiting fees of $78K.

Interest expense$542K-10% YoY

Lower interest expense despite new Term Loan D debt incurred for APM acquisition.

Margins: Gross margin declined 3 percentage points YoY to 30% for the nine-month period, driven by unfavorable product mix and higher manufacturing under-absorption and inventory reserves related to next-generation handpiece components. Operating margin also compressed as G&A expenses increased 42% YoY, reflecting APM integration costs and elevated personnel expenses.

Watch Items from the Filing

Customer concentration: largest customer represents 79% of nine-month sales ($44.9M) and 75% of accounts receivable ($14.6M); contract extended through 2028.
Repair revenue declined 36% YoY ($5.4M decrease) as legacy handpiece repairs decline; no guarantee customer will purchase new generation Helios driver.
Zimmer Biomet acquisition of Monogram completed October 2025; company received $8.9M in cash and 2.2M contingent value rights worth up to $12.4M if five milestones achieved; first milestone completed Q3 FY2026 generating $2.3M additional gain.
Total debt outstanding increased to $18.5M at March 31, 2026 (vs. $15.4M at June 30, 2025); additional $11M available on revolving line with UMB Bank.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q3 2026

$19.9M

Net Income

Q3 2026

$3.9M

Free Cash Flow

Q3 2026

$1.5M

Operating Margin

Q3 2026

15.5%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+16.8% YoY

$53.8MFY 2024

FY20 $34.8MFY22 $42.0MFY23 $46.1MFY24 $53.8M

Net Income

-69.9% YoY

$2.1MFY 2024

FY20 $6.1MFY22 $4.6MFY23 $7.1MFY24 $2.1M

Operating Income

+24.5% YoY

$7.2MFY 2024

FY20 $7.1MFY22 $5.1MFY23 $5.8MFY24 $7.2M

EPS (Diluted)

-69.2% YoY

$0.60FY 2024

FY20 $1.50FY22 $1.21FY23 $1.95FY24 $0.60

Total Assets

+1.3% YoY

$52.5MFY 2024

FY20 $31.1MFY22 $49.1MFY23 $51.8MFY24 $52.5M

Total Debt

-6.6% YoY

$12.0MFY 2024

FY20 $4.6MFY22 $13.6MFY23 $12.8MFY24 $12.0M

Op. Cash Flow

+14.0% YoY

$6.2MFY 2024

FY20 $4.9MFY22 $-847.0KFY23 $5.5MFY24 $6.2M

Metric	FY 2024	FY 2023	FY 2022	FY 2020	FY 2018	FY 2016
Revenue	$53.8M +16.8%	$46.1M +9.6%	$42.0M +20.7%	$34.8M +55.1%	$22.5M +11.4%	$20.2M
Net Income	$2.1M -69.9%	$7.1M +54.7%	$4.6M -25.2%	$6.1M +277.1%	$1.6M +97.2%	$822.0K
Operating Income	$7.2M +24.5%	$5.8M +12.5%	$5.1M -27.5%	$7.1M +195.4%	$2.4M +196.4%	$807.0K
EPS (Diluted)	$0.60 -69.2%	$1.95 +61.2%	$1.21 -19.3%	$1.50 +305.4%	$0.37 +85.0%	$0.20
Total Assets	$52.5M +1.3%	$51.8M +5.6%	$49.1M +57.7%	$31.1M +56.3%	$19.9M +78.7%	$11.1M
Total Debt	$12.0M -6.6%	$12.8M -5.8%	$13.6M +193.6%	$4.6M +11190.2%	$41.0K -10.9%	$46.0K
Operating Cash Flow	$6.2M +14.0%	$5.5M +744.9%	$-847.0K -117.1%	$4.9M +59.7%	$3.1M +564.4%	$466.0K

AI Insight: PDEX Ratio Trends

PRO DEX shows highly volatile quarterly performance with ROIC swinging from 10.3% to 41.3% over the past two years.

• Operating margin fluctuated dramatically from 7.7% in Q2 2025 to 20.9% in Q1 2025, indicating unstable operational performance.

• ROE peaked at 45.1% in Q3 2025 but declined to 21.0% in Q4 2025, showing inconsistent profitability patterns.

• ROIC volatility remains extreme, ranging from 10.3% to 41.3% across recent quarters with no clear directional trend.

⚠ Significant quarter-to-quarter margin swings suggest potential operational or market challenges requiring closer monitoring.

⚠ Limited debt-to-equity data points make it difficult to assess capital structure stability and leverage trends.

Get alerted when PDEX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PRO DEX INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PDEX

BlackRock, Inc.
$7.5M152,515 sh
VANGUARD CAPITAL MANAGEMENT LLC
$5.5M111,330 sh
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.
$3.0M61,735 sh
DIMENSIONAL FUND ADVISORS LP
$2.8M56,941 sh
GEODE CAPITAL MANAGEMENT, LLC
$2.4M48,347 sh
NORTHERN TRUST CORP
$2.3M46,691 sh
STATE STREET CORP
$1.6M33,114 sh
Quadrature Capital Ltd
$736.1K14,986 sh
MORGAN STANLEY
$698.1K14,213 sh
BNP PARIBAS FINANCIAL MARKETS
$650.1K13,234 sh

Fund	Value	Shares
BlackRock, Inc.	$7.5M	152,515
VANGUARD CAPITAL MANAGEMENT LLC	$5.5M	111,330
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.	$3.0M	61,735
DIMENSIONAL FUND ADVISORS LP	$2.8M	56,941
GEODE CAPITAL MANAGEMENT, LLC	$2.4M	48,347
NORTHERN TRUST CORP	$2.3M	46,691
STATE STREET CORP	$1.6M	33,114
Quadrature Capital Ltd	$736.1K	14,986
MORGAN STANLEY	$698.1K	14,213
BNP PARIBAS FINANCIAL MARKETS	$650.1K	13,234

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PDEX on your watchlist

Track score changes the day PRO DEX INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PDEX a good stock to buy?

13F Pro's AI-powered analysis of PRO DEX INC (PDEX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PDEX are available on the PDEX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PDEX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PDEX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PRO DEX INC's investment landscape.